Lauren Scarborough
Family · Greenville, SCNPI 1679097794
Payments from drug & device makers
Across 80 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$330
- Novartis$196
- Neurocrine Biosciences, Inc.$165
- TG Therapeutics, Inc.$158
- Teva Pharmaceuticals USA, Inc.$80
- Averitas Pharma Inc.$69
- plus $527 from 17 others
What the payments were for
- Food & beverage$1,524100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $330 |
| Novartis | 9 | $196 |
| Neurocrine Biosciences, Inc. | 7 | $165 |
| TG Therapeutics, Inc. | 7 | $158 |
| Teva Pharmaceuticals USA, Inc. | 5 | $80 |
| Averitas Pharma Inc. | 3 | $69 |
| Genentech USA, Inc. | 2 | $56 |
| AstraZeneca | 2 | $54 |
| Lilly USA, LLC | 3 | $51 |
| UCB, Inc. | 2 | $43 |
| Neurelis, Inc. | 2 | $40 |
| Eisai Inc. | 1 | $31 |
| SK Life Science, Inc. | 1 | $28 |
| Abbott | 1 | $28 |
| GRT US Holding, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $17 |
| Biogen | 1 | $13 |
How this compares
$1,524 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 27 | $670 |
| Topiramate | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other family in Greenville
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Carrie HendersonGreenville$91K
- Michelle StrongGreenville$55K
- Melissa BrownlowGreenville$20K
- Sarah McNightGreenville$15K
- Melissa MotesGreenville$13K
- Matthew KeatonGreenville$10K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.